Drug Trial Radar · NCT06732648
The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction
Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
725
Planned (sponsor's estimate)
Start
Feb 7, 2025
Primary completion
Jun 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy, and safety of HRS8179 injection in preventing and treating severe cerebral edema after large area cerebral infarction in the cerebral hemisphere
Conditions
- Severe Cerebral Edema Following Large Hemispheric Infarction
Interventions
HRS8179 injectionDrug
HRS8179 injection; high dose
HRS8179 blank preparation.Drug
HRS8179 blank preparation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mortality rate at Day 90Time frame: at Day 90
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.